Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
Bahr GM, De La Tribonniere X, Darcissac E, Ajana F, Bocket L, Sissoko D, Yazdanpanah Y, Dewulf J, Amiel C, Mouton Y. Bahr GM, et al. Among authors: darcissac e. J Antimicrob Chemother. 2003 Jun;51(6):1377-88. doi: 10.1093/jac/dkg244. Epub 2003 Apr 25. J Antimicrob Chemother. 2003. PMID: 12716777 Clinical Trial.
Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.
Vidal VF, Castéran N, Riendeau CJ, Kornfeld H, Darcissac EC, Capron A, Bahr GM. Vidal VF, et al. Among authors: darcissac ec. Eur J Immunol. 2001 Jul;31(7):1962-71. doi: 10.1002/1521-4141(200107)31:7<1962::aid-immu1962>3.0.co;2-v. Eur J Immunol. 2001. PMID: 11449348 Free article.
38 results